Evaxion begins experimental testing of two AI-Immunology autoimmune treatment concepts
Reuters2026/09/14 12:04- Evaxion expanded its AI-Immunology platform into autoimmune diseases, testing two new treatment concepts in experimental studies.
- Initial results have not been presented yet; the company plans to present experimental data on November 18, 2026 at PEGS Europe.
- The programs aim to target underlying disease drivers, seeking improved efficacy with fewer side effects than current symptom-focused therapies.
- Management framed the move as a strategic expansion into a high unmet-need area with partnership potential across drug development stages.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic partners with Trump-linked company RUM Group (RUM.US)! $13.7 billion computing power deal sparks concerns over conflicts of interest
Anthropic has signed a six-year computing power contract worth a total of 13.7 billions USD with RUM Group. The latter's close ties to Trump have also raised concerns about potential conflicts of interest.
Aberdeen says Japan retail equity holdings top UK despite later investor push
Texas Capital Bancshares Moves Stock Listing to Texas Stock Exchange
NextEra Energy Reaffirms Full-Year Adjusted Earnings Outlook
Crypto prices
More
